

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF CR SANJIU FOR THE YEAR ENDED 31 DECEMBER 2022

On 19 January 2023, CR Sanjiu released its results estimate for the year ended 31 December 2022.

China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”) is a company incorporated in the People’s Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 62.99% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 19 January 2023, CR Sanjiu released its results estimate for the year ended 31 December 2022, in which, it announced that the net profit attributable to the shareholders of CR Sanjiu for the year ended 31 December 2022 is estimated to range from approximately RMB2,365 million to RMB2,570 million (as compared to the same period last year of net profit of approximately RMB2,055.6437 million), net profit attributable to the shareholders of CR Sanjiu excluding non-recurring gain or loss is estimated to range from approximately RMB2,150 million to RMB2,320 million (as compared to the same period last year of net profit of approximately RMB1,852.9168 million), basic earnings per share is estimated to range from approximately RMB2.4 per share to approximately RMB2.61 per share (as compared to the same period last year of profit per share of approximately RMB2.1 per share) (the “**CR Sanjiu Results Estimate**”).

The reasons for the change in results are that, following the industrial development trend, CR Sanjiu actively responded to market changes, continued its innovative transformation and upgrade, and constantly strengthened its brand building and optimized its product structure in order to enhance its profitability.

The CR Sanjiu Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2022 to be issued by CR Sanjiu shall prevail. The financial information in this announcement is limited to CR Sanjiu only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 20 January 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.